Cost-effectiveness analysis of intra-articular injections of a high molecular weight bioengineered hyaluronic acid for the treatment of osteoarthritis knee pain

References

• Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58:26-35
   PubMed Web of Science ®Google Scholar
• Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-62
   PubMed Web of Science ®Google Scholar
• Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011;377:2115-26
   PubMed Web of Science ®Google Scholar
• Pereira D, Peleteiro B, Araujo J, et al. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthritis Cartilage 2011;19:1270-85
   PubMed Web of Science ®Google Scholar
• Bitton R. The economic burden of osteoarthritis. Am J Manag Care 2009;15(8 Suppl):S230-5
   PubMedGoogle Scholar
• Murphy L, Helmick CG. The impact of osteoarthritis in the United States: a population-health perspective: a population-based review of the fourth most common cause of hospitalization in U.S. adults. Orthop Nurs 2012;31:85-91
   PubMed Web of Science ®Google Scholar
• Murphy L, Schwartz TA, Helmick CG, et al. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum 2008;59:1207-13
   PubMed Web of Science ®Google Scholar
• Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum 2006;54:226-9
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Prevalence and most common causes of disability among adults–United States, 2005. MMWR Morb Mortal Wkly Rep 2009;58:421-6
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions–United States, 2003. MMWR Morb Mortal Wkly Rep 2007;56:4-7
   PubMedGoogle Scholar
• US Department of Labor. Bureau of Labor Statistics. CPI Inflation Calculator—2012. Washington, DC. Available at: http://www.bls.gov/data/inflation_calculator.htm. Accessed April 16, 2013
   Google Scholar
• Torio CM, Andrews RM. National inpatient hospital costs: the most expensive conditions by payer, 2011. HCUP Statistical Brief #160. Rockville, MD: Agency for Healthcare Research and Quality, August 2013
   Google Scholar
• Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006;2:CD005321
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012;64:465-74
   PubMed Web of Science ®Google Scholar
• Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 2006;14:154-62
   PubMed Web of Science ®Google Scholar
• Altman RD, Rosen JE, Bloch DA, et al. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial). Semin Arthritis Rheum 2009;39:1-9
   PubMed Web of Science ®Google Scholar
• Altman RD, Rosen JE, Bloch DA, et al. Safety and efficacy of retreatment with a bioengineered hyaluronate for painful osteoarthritis of the knee: results of the open-label Extension Study of the FLEXX Trial. Osteoarthritis Cartilage 2011;19:1169-75
   PubMed Web of Science ®Google Scholar
• Hatoum HT, Rosen JE, Fierlinger AL, et al. Assessment of the health-related quality of life impact of EUFLEXXA® (1% Sodium Hyaluronate) using short form 36 (SF-36) data collected in a randomized clinical trial evaluating treatment of osteoarthritis knee pain. 2013 World Congress on Osteoarthritis; April 18–21, 2013; Philadelphia, PA
   Google Scholar
• Ramsey S, Willke R, Briggs A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 2005;8:521-33
   PubMed Web of Science ®Google Scholar
• Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices–Modeling Studies. Value Health 2003;6:9-17
   PubMed Web of Science ®Google Scholar
• Torrance GW, Raynauld JP, Walker V, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results. Osteoarthritis Cartilage 2002;10:518-27
   PubMed Web of Science ®Google Scholar
• Kahan A, Lleu PL, Salin L. Prospective randomized study comparing the medicoeconomic benefits of Hylan GF-20 vs. conventional treatment in knee osteoarthritis. Joint Bone Spine 2003;70:276-81
   PubMed Web of Science ®Google Scholar
• Waddell D, Rein A, Panarites C, et al. Cost implications of introducing an alternative treatment for patients with osteoarthritis of the knee in a managed care setting. Am J Manag Care 2001;7:981-91
   PubMed Web of Science ®Google Scholar
• Mazieres B, Bard H, Ligier M, et al. Medicoeconomic evaluation of hyaluronic acid for knee osteoarthritis in everyday practice: the MESSAGE study. Joint Bone Spine 2007;74:453-60
   Google Scholar
• Turajane T, Labpiboonpong V, Maungsiri S. Cost analysis of intra-articular sodium hyaluronate treatment in knee osteoarthritis patients who failed conservative treatment. J Med Assoc Thai 2007;90:1839-44
   Google Scholar
• Yen ZS, Lai MS, Wang CT, et al. Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan. J Rheumatol 2004;31:1797-803
   PubMedGoogle Scholar
• Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008;8:165-78
   PubMedGoogle Scholar
• Raynauld JP, Torrance GW, Band PA, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage 2002;10:506-17
   PubMed Web of Science ®Google Scholar
• Grootendorst P, Marshall D, Pericak D, et al. A model to estimate health utilities index mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the knee. J Rheumatol 2007;34:534-42
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. Physician fee schedule look-up. Baltimore, MD. Available at: http://www.cms.hhs.gov/PFSlookup/. Accessed April 16, 2013
   Google Scholar
• Lee DW, Meyer JW, Clouse J. Implications of controlling for comorbid conditions in cost-of-illness estimates: a case study of osteoarthritis from a managed care system perspective. Value Health 2001;4:329-34
   PubMedGoogle Scholar
• MacLean CH, Knight K, Paulus H, et al. Costs attributable to osteoarthritis. J Rheumatol 1998;25:2213-8
   PubMed Web of Science ®Google Scholar
• Losina E, Daigle ME, Suter LG, et al. Disease-modifying drugs for knee osteoarthritis: can they be cost-effective? Osteoarthritis Cartilage 2013;21:655-67
   PubMed Web of Science ®Google Scholar
• Lussier A, Cividino AA, McFarlane CA, et al. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol 1996;23:1579-85
   PubMed Web of Science ®Google Scholar
• Berger A, Bozic K, Stacey B, et al. Patterns of pharmacotherapy and health care utilization and costs prior to total hip or total knee replacement in patients with osteoarthritis. Arthritis Rheum 2011;63:2268-75
   PubMedGoogle Scholar
• Kamath CC, Kremers HM, Vanness DJ, et al. The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. Value Health 2003;6:144-57
   PubMed Web of Science ®Google Scholar
• Mapel DW, Shainline M, Paez K, et al. Hospital, pharmacy, and outpatient costs for osteoarthritis and chronic back pain. J Rheumatol 2004;31:573-83
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Crowson CS, Campion ME, et al. Direct medical costs unique to people with arthritis. J Rheumatol 1997;24:719-25
   PubMed Web of Science ®Google Scholar
• Waddell DD, Bricker DC. Total knee replacement delayed with Hylan G-F 20 use in patients with grade IV osteoarthritis. J Manag Care Pharm 2007;13:113-21
   PubMed Web of Science ®Google Scholar
• Waddell DD. Viscosupplementation with hyaluronans for osteoarthritis of the knee: clinical efficacy and economic implications. Drugs Aging 2007;24:629-42
   PubMed Web of Science ®Google Scholar
• Arnold W, Fullerton DS, Holder S, et al. Viscosupplementation: managed care issues for osteoarthritis of the knee. J Manag Care Pharm 2007;13(4 Suppl):S3-19; quiz S20–22.
   Google Scholar